<DOC>
	<DOC>NCT03093480</DOC>
	<brief_summary>The primary purpose of this study is to describe the time to tolerization with rFVIIIFc in participants within a maximum of 12 months of ITI treatment.</brief_summary>
	<brief_title>A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Ability of the participant or his legally authorized representative (e.g., parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local participant privacy regulations Male participants of any age diagnosed with severe hemophilia A (as confirmed from the medical record) Diagnosed with high titer inhibitors (historical peak greater than or equal to (&gt;=) 5 Bethesda units per milliliter (BU/mL), according to medical records) Previously treated with any plasmaderived or recombinant conventional or Extended HalfLife FVIII Other coagulation disorder(s) in addition to hemophilia A Previous immune tolerance induction (ITI) History of hypersensitivity or anaphylaxis associated with any recombinant coagulation factor VIII Fc (rFVIIIFc) administration Planned major surgery to be deferred after study completion (minor surgery such as tooth extraction or insertionreplacement of central venous access device is allowed) Abnormal renal function (serum creatinine greater than [&gt;] 2.0 milligram per deciliter [mg/dL]) as assessed by local laboratory Serum alanine aminotransferase or aspartate aminotransferase &gt; 5 Ã— upper limit of normal (ULN) as assessed by local laboratory</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>